130 related articles for article (PubMed ID: 29429248)
21. [Effects of Clinical Characteristics, Laboratory Parameters and Treatment Regimens on Prognosis of Patients with Multiple Myeloma].
Xu L; Chen ZL; Hu M; Tao S; Chen Y; Su GH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Aug; 27(4):1166-1172. PubMed ID: 31418374
[TBL] [Abstract][Full Text] [Related]
22. Short progression-free survival predicts for poor overall survival in older patients with multiple myeloma treated upfront with novel agent-based therapy.
Migkou M; Kastritis E; Roussou M; Gkotzamanidou M; Gavriatopoulou M; Nikitas N; Mparmparoussi D; Matsouka C; Gika D; Terpos E; Dimopoulos MA
Eur J Haematol; 2011 Oct; 87(4):323-9. PubMed ID: 21631590
[TBL] [Abstract][Full Text] [Related]
23. Alpha-interferon maintenance treatment is associated with improved survival after high-dose treatment and autologous stem cell transplantation in patients with multiple myeloma: a retrospective registry study from the European Group for Blood and Marrow Transplantation (EBMT).
Björkstrand B; Svensson H; Goldschmidt H; Ljungman P; Apperley J; Mandelli F; Marcus R; Boogaerts M; Alegre A; Remes K; Cornelissen JJ; Bladé J; Lenhoff S; Iriondo A; Carlson K; Volin L; Littlewood T; Goldstone AH; San Miguel J; Schattenberg A; Gahrton G
Bone Marrow Transplant; 2001 Mar; 27(5):511-5. PubMed ID: 11313685
[TBL] [Abstract][Full Text] [Related]
24. [Clinical Analysis of Multiple Myeloma Patients Aged over 80 Years].
Shen M; Jiang XX; An N; Zhang JJ; Huang ZX; Li X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Apr; 24(2):463-8. PubMed ID: 27151011
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of up-front treatment with a double stem cell transplantation in multiple myeloma.
Eom KS; Min CK; Lee S; Kim YJ; Kim SY; Kim HJ; Lee JW; Min WS; Kim CC
Jpn J Clin Oncol; 2006 Jul; 36(7):432-8. PubMed ID: 16782727
[TBL] [Abstract][Full Text] [Related]
26. [Efficacy of lobaplatin plus S-1 and the predictive value of circulating tumor cell in patients with advanced gastric cancer].
Feng Q; Zhao JR; Zhang AX; Li SL
Zhonghua Zhong Liu Za Zhi; 2018 Sep; 40(9):696-702. PubMed ID: 30293397
[No Abstract] [Full Text] [Related]
27. Outcome and characteristics of nonsecretory multiple myeloma compared with secretory multiple myeloma: a retrospective multicenter study from China.
Sun H; Liu A; Liu L; Wang W; Cai Z; Yan H; Chen L; Gao G; Wang F; Liao A; Chen B; Feng J; Li J; Huang DP; Gao D; Zhang QK; Luo J; Fu R; Du J; Lu J
BMC Cancer; 2023 Oct; 23(1):930. PubMed ID: 37784037
[TBL] [Abstract][Full Text] [Related]
28. [Expression of CD45 in newly diagnosed multiple myeloma and the relationship with prognosis].
Shi J; Zhu ZM; Sun K; Lei PC; Liu ZW; Guo JM; Yang J; Zang YZ; Zhang Y
Zhonghua Xue Ye Xue Za Zhi; 2019 Sep; 40(9):744-749. PubMed ID: 31648475
[No Abstract] [Full Text] [Related]
29. Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk Cytogenetics.
Chakraborty R; Muchtar E; Kumar SK; Jevremovic D; Buadi FK; Dingli D; Dispenzieri A; Hayman SR; Hogan WJ; Kapoor P; Lacy MQ; Leung N; Gertz MA
Biol Blood Marrow Transplant; 2017 Apr; 23(4):598-605. PubMed ID: 28115277
[TBL] [Abstract][Full Text] [Related]
30. Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma.
Anagnostopoulos A; Aleman A; Ayers G; Donato M; Champlin R; Weber D; Alexanian R; Giralt S
Cancer; 2004 Jun; 100(12):2607-12. PubMed ID: 15197803
[TBL] [Abstract][Full Text] [Related]
31. Impact of early use of lenalidomide and low-dose dexamethasone on clinical outcomes in patients with relapsed/refractory multiple myeloma.
Kobayashi T; Kuroda J; Fuchida S; Kaneko H; Yagi H; Shibayama H; Tanaka H; Kosugi S; Uoshima N; Kobayashi M; Adachi Y; Ohta K; Ishii K; Uchiyama H; Matsuda M; Nakatani E; Tsudo M; Shimazaki C; Takaori-Kondo A; Nomura S; Matsumura I; Taniwaki M; Kanakura Y;
Int J Hematol; 2015 Jan; 101(1):37-45. PubMed ID: 25385278
[TBL] [Abstract][Full Text] [Related]
32. Clinical course and prognosis of non-secretory multiple myeloma.
Chawla SS; Kumar SK; Dispenzieri A; Greenberg AJ; Larson DR; Kyle RA; Lacy MQ; Gertz MA; Rajkumar SV
Eur J Haematol; 2015 Jul; 95(1):57-64. PubMed ID: 25382589
[TBL] [Abstract][Full Text] [Related]
33. Primary systemic amyloidosis with delayed progression to multiple myeloma.
Rajkumar SV; Gertz MA; Kyle RA
Cancer; 1998 Apr; 82(8):1501-5. PubMed ID: 9554527
[TBL] [Abstract][Full Text] [Related]
34. [Therapeutic effects and prognostic factors for the limited-stage small cell lung cancer treated with multidisciplinary therapy].
Dong XJ; Wang MZ; Zhong W; Zhang L; Zhang XT; Zhao J; Xia Y; Li LY
Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):216-21. PubMed ID: 22780978
[TBL] [Abstract][Full Text] [Related]
35. Additional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patients.
Grzasko N; Hus M; Pluta A; Jurczyszyn A; Walter-Croneck A; Morawska M; Chocholska S; Hajek R; Dmoszynska A
Hematol Oncol; 2013 Mar; 31(1):41-8. PubMed ID: 22674819
[TBL] [Abstract][Full Text] [Related]
36. Systemic Treatments for Metastatic Renal Cell Carcinoma: 10-Year Experience of Immunotherapy and Targeted Therapy.
Kim SH; Park WS; Kim SH; Joung JY; Seo HK; Lee KH; Chung J
Cancer Res Treat; 2016 Jul; 48(3):1092-101. PubMed ID: 26875203
[TBL] [Abstract][Full Text] [Related]
37. The evolving diagnosis and treatment paradigms of multiple myeloma in China: 15 years' experience of 1256 patients in a national medical center.
Yang Y; Li J; Wang W; Wang Y; Maihemaiti A; Ren L; Lan T; Zhou C; Li P; Wang P; Aihemaiti X; Chen F; Xu T; Xu J; Liu P
Cancer Med; 2023 Apr; 12(8):9604-9614. PubMed ID: 36807775
[TBL] [Abstract][Full Text] [Related]
38. Immunoglobulin D Multiple Myeloma: Disease Profile, Therapeutic Response, and Survival.
Wang GR; Sun WJ; Chen WM; Huang ZX; Zhang JJ; An N; Shen M; Li X
Acta Haematol; 2016; 136(3):140-6. PubMed ID: 27409804
[TBL] [Abstract][Full Text] [Related]
39. Improved clinical outcomes for multiple myeloma patients treated at a single specialty clinic.
Berenson A; Vardanyan S; David M; Wang J; Harutyunyan NM; Gottlieb J; Halleluyan R; Spektor TM; Udd KA; Eshaghian S; Nassir Y; Eades B; Swift R; Berenson JR
Ann Hematol; 2017 Mar; 96(3):441-448. PubMed ID: 27913860
[TBL] [Abstract][Full Text] [Related]
40. Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study.
Morabito F; Bringhen S; Larocca A; Wijermans P; Victoria Mateos M; Gimsing P; Mazzone C; Gottardi D; Omedè P; Zweegman S; José Lahuerta J; Zambello R; Musto P; Magarotto V; Schaafsma M; Oriol A; Juliusson G; Cerrato C; Catalano L; Gentile M; Isabel Turel A; Marina Liberati A; Cavalli M; Rossi D; Passera R; Rosso S; Beksac M; Cavo M; Waage A; San Miguel J; Boccadoro M; Sonneveld P; Palumbo A; Offidani M
Am J Hematol; 2014 Apr; 89(4):355-62. PubMed ID: 24273190
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]